Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2010

View Archived Issues

Scientists shed light on protective role of DJ-1 in Parkinson's disease and isradipine potential

ACT-178882/MK-1597 shows suitable profile for development for hypertension

Chimerix's CMX-157 is safe in first-in-human study in healthy volunteers

Novartis submits MAA to EMA for multi-component meningococcal b vaccine Bexsero

TetraLogic Pharmaceuticals claims new inhibitors of apoptosis protein inhibitors

Corcept presents phase III data for Corlux for Cushing's syndrome

Bayer Schering Pharma claims novel antagonists of proteinase-activated receptor 1

Astellas Pharma patents new inhibitors of protein kinase C theta

Cylene Pharmaceuticals divulges novel inhibitors of protein kinases

Cyclacel's cell cycle inhibitor CYC-065 suppresses growth of MM cell in vitro

HDAC inhibitor PCI-24781 displays in vivo anti-inflammatory effects

Arena and Eisai attend end-of-review meeting with FDA for lorcaserin

FDA warns about abnormal heart rhythms associated with dolasetron mesylate

Phase IIb study begins of Azixa as front-line treatment for glioblastoma multiforme

Dynavax reports data from phase Ib study of hepatitis B therapeutic vaccine DV-601

Alimera Sciences receives FDA complete response for Iluvien

New orexin receptor OX2 antagonists described by Merck & Co.

Novartis receives E.U. approval for Tasigna in newly diagnosed Ph+ CML

Teva receives FDA complete response letter for lower-volume glatiramer acetate

DSM to add to nutrition segment through acquisition of Martek

Enrollment completed in phase II study of belinostat in carcinoma of unknown primary

BioCrossroads provides support to Aarden for TB program

Oramed receives grant to support its diabetes research

Stem Cell Therapeutics meets with FDA for NTx-265 program

Meda obtains rights to market EpiPen auto-injector in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...